Headquartered at the New Jersey Institute of Technology, US life science company BioNeutral Group says it has received a favourable legal opinion on the manufacture and marketing of the hospital-grade formulation of its antimicrobial Ygiene within the UK, France and Sweden. The company has already received permission to market Ygiene in Germany.
BioNeutral plans to manufacture and market Ygiene throughout the EU. The company’s legal team has advised that the UK, France and Sweden require only basic notification to the national authorities before sales of Ygiene commence within each of these countries.
The president and ceo of BioNeutral Group, Stephen Browand, said: “As BioNeutral seeks to expand its product sales across Europe, it is first necessary that we carefully evaluate the requirements of each EU member state with regard to the marketing of biocides.
“The opinion we have received from our UK legal team indicates that the UK, France and Sweden can quickly join Germany in becoming the next European markets for Ygiene, a development that would significantly boost our potential global market presence.”
The company has also received test results from an independent testing company, ATS Labs, indicating that the antimicrobial has passed the stringent Good Laboratory Practice test requirements for hospital and medical environment efficacy claims.
BioNeutral says this key test was also performed in the presence of protein, which indicates there is no need to clean surfaces before disinfecting, thus micro-organisms can be eliminated in two minutes or less.
Dr Andrew Kielbania, chief scientist at BioNeutral, said: “Our goal at BioNeutral is to deliver a unique and effective broad spectrum antimicrobial that will eliminate health threatening micro-organisms in one short contact time. This will insure a high level of disinfecting and will eliminate end user confusion and uncertainty.”
In addition to a variety of virus strains, Ygiene has been proven to kill spores, including the difficult to eradicate C. difficile and anthrax spores.
